AstraZeneca and Eli Lilly Partner to Develop BACE Inhibitor in Risk-Sharing Deal
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 10 (Table of Contents)
Published: 9 Oct-2014
DOI: 10.3833/pdr.v2014.i10.2066 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In a deal that makes considerable sense for both parties, AstraZeneca and Eli Lilly have joined forces to develop and commercialise AZD3293, AstraZeneca’s oral beta secretase cleaving enzyme (BACE) inhibitor for the potential treatment of Alzheimer’s disease (AD)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS